Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 3/20 | 0.60 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.60 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.57 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.57 |
| ▸ | EPHX2 | P34913 | 2/20 | 0.49 |
| ▸ | NPSR1 | Q6W5P4 | 2/20 | 0.49 |
| ▸ | MAPT | P10636 | 4/20 | 0.47 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.46 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.46 |
| ▸ | MEN1 | O00255 | 1/20 | 0.45 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.45 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.45 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.45 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.44 |
| ▸ | NPC1 | O15118 | 1/20 | 0.44 |
| ▸ | RORA | P35398 | 1/20 | 0.44 |
| ▸ | NR5A1 | Q13285 | 1/20 | 0.44 |
| ▸ | ALDH2 | P05091 | 1/20 | 0.43 |
| ▸ | PPARG | P37231 | 1/20 | 0.43 |
| ▸ | PPARA | Q07869 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10487619 | 1.00 | LMNA (0.60) | LMNAL3MBTL1KMT2AALDH1A1EPHX2 | |
| SCHEMBL3369250 | 1.00 | LMNA (0.60) | LMNAL3MBTL1KMT2AALDH1A1EPHX2 | |
| SCHEMBL10879122 | 0.95 | LMNA (0.56) | LMNAL3MBTL1KMT2AALDH1A1EPHX2 | |
| SCHEMBL11513919 | 0.89 | LMNA (0.76) | LMNAL3MBTL1KMT2AALDH1A1EPHX2 | |
| SCHEMBL10430471 | 0.87 | ALDH1A1 (0.51) | LMNAL3MBTL1KMT2AALDH1A1EPHX2 | |
| SCHEMBL11548487 | 0.86 | L3MBTL1 (0.63) | LMNAL3MBTL1KMT2AALDH1A1EPHX2 | |
| SCHEMBL5205374 | 0.86 | LMNA (0.63) | LMNAL3MBTL1KMT2AALDH1A1EPHX2 | |
| SCHEMBL9857703 | 0.86 | LMNA (0.63) | LMNAL3MBTL1KMT2AALDH1A1EPHX2 | |
| SCHEMBL18562096 | 0.86 | LMNA (0.63) | LMNAL3MBTL1KMT2AALDH1A1EPHX2 | |
| SCHEMBL9063261 | 0.86 | LMNA (0.63) | LMNAL3MBTL1KMT2AALDH1A1EPHX2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2010065024-A1 | TOPICAL TREATMENT OF CATARACTS IN DOGS | KADOR PETER F (US) | 2010-06-10 | — | — | WO | claimed |
| US-20090082415-A1 | Topical treatment of cataracts in dogs | BOARD OF REGENTS OF THE UNIVERSITY OF NEBRASKA | 2009-03-26 | — | — | US | claimed |
| US-20220409566-A1 | CCL5 Inhibitors | LAPKO INC, dba AFECTA PHARMACEUTICALS | 2022-12-29 | — | — | US | disclosed |
| US-20220142961-A1 | CCL5 Inhibitors | LAPKO INC, dba AFECTA PHARMACEUTICALS | 2022-05-12 | — | — | US | disclosed |
| US-11318111-B2 | CCL5 inhibitors | LAPKO INC (US) | 2022-05-03 | — | — | US | disclosed |
| US-20210196665-A1 | CCL5 Inhibitors | AFECTA PHARMACEUTICALS, INC. (US) | 2021-07-01 | — | — | US | disclosed |
| US-10940132-B2 | CCL5 inhibitors | AFECTA PHARMACEUTICALS, INC. (US) | 2021-03-09 | — | — | US | disclosed |
| US-20200138766-A1 | CCL5 INHIBITORS | LAPKO INC. DBA AFECTA PHARMACEUTICALS | 2020-05-07 | — | — | US | disclosed |
| US-8158667-B2 | Topical treatment of cataracts in dogs | BOARD OF REGENTS OF THE UNIVERSITY OF NEBRASKA | 2012-04-17 | — | — | US | disclosed |
| WO-2010065024-A1 | TOPICAL TREATMENT OF CATARACTS IN DOGS | KADOR PETER F (US) | 2010-06-10 | — | — | WO | disclosed |
| US-20090082415-A1 | Topical treatment of cataracts in dogs | BOARD OF REGENTS OF THE UNIVERSITY OF NEBRASKA | 2009-03-26 | — | — | US | disclosed |
| US-4853410-A | Hydroxyacetic acid derivatives for the treatment of diabetic complications | PFIZER INC. (US) | 1989-08-01 | — | — | US | disclosed |
| WO-1987004344-A1 | HYDROXYACETIC ACID DERIVATIVES FOR THE TREATMENT OF DIABETIC COMPLICATIONS | PFIZER INC. (US) | 1987-07-30 | — | — | WO | disclosed |
| EP-0230379-A2 | Chroman- and thiochroman-4-acetic acids useful in the treatment of diabetic complications | PFIZER INC. (US) | 1987-07-29 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220142961-A1 | CCL5 Inhibitors | CCL5, CCL11, CCR5 | LMNA 4533/4885L3MBTL1 1170/4885KMT2A 4842/4885 |
| US-20200138766-A1 | CCL5 INHIBITORS | CCL5, CCL11, CCR5 | LMNA 4533/4885L3MBTL1 1170/4885KMT2A 4842/4885 |
| US-20090082415-A1 | Topical treatment of cataracts in dogs | AKR1A1, AKR1B1, AKR1C1 | LMNA 3186/4885L3MBTL1 3978/4885KMT2A 1436/4885 |
| US-20210196665-A1 | CCL5 Inhibitors | CCL5, CCL11, CCR5 | LMNA 4533/4885L3MBTL1 1170/4885KMT2A 4842/4885 |
| US-10940132-B2 | CCL5 inhibitors | CCL5, CCL11, CCR5 | LMNA 4533/4885L3MBTL1 1170/4885KMT2A 4842/4885 |
| US-11318111-B2 | CCL5 inhibitors | CCL5, CCL11, CCR5 | LMNA 4533/4885L3MBTL1 1170/4885KMT2A 4842/4885 |
| US-20220409566-A1 | CCL5 Inhibitors | CCL5, CCL11, CCR5 | LMNA 4533/4885L3MBTL1 1170/4885KMT2A 4842/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.